PuriCore Plc Board Changes (3100V)
10 Enero 2013 - 10:53AM
UK Regulatory
TIDMPURI
RNS Number : 3100V
PuriCore Plc
10 January 2013
10 January 2013
PuriCore plc
("PuriCore" or the "Company")
Board Changes
PuriCore (LSE: PURI), the water-based, clean technology company,
today announces Board changes. In line with corporate governance
best practice and following his long-standing service as a
Non-Executive Director, Mike Sapountzoglou is stepping down with
effect from 11 January 2013. The Company also announces that Daniel
Hegglin will join PuriCore as a Non-Executive Director.
Mr. Hegglin offers more than 30 years of experience in
international finance. He is currently a partner at TT
International, a Hong Kong investment management fund, where he is
responsible for its hedge fund and Asia businesses. Mr. Hegglin was
previously with Morgan Stanley in Europe and Asia for 24 years.
Mr. Hegglin's appointment as a Non-Executive Director will be
effective upon admission to listing and trading of the new ordinary
shares to be issued by the Company following approval of the
resolution at the General Meeting of the Company held earlier
today. Admission is expected on 11 January 2013. Mr. Hegglin will,
immediately following admission, hold 3,309,091 shares in the
Company, being 6.61 per cent. of the enlarged issued share
capital.
The Company confirms that there is no additional information
about Mr. Hegglin that the Company is required to disclose under
paragraph 9.6.13(1) to (6) of the Listing Rules of the UK Listing
Authority.
Michael Ashton, Executive Chairman, said:
"Mike's decision to leave comes at a time when the Company is
entering an exciting new phase, to which he has been an integral
part, and we wish him well for the future. The addition of Danny,
whom I've recently come to know and respect, will refresh the Board
with additional financial sector experience."
Enquiries:
UK US
FTI Consulting Sage Strategic Marketing
Susan Stuart/Simon Jennifer Guinan
Conway
Victoria Foster Mitchell +1 610 410 8111
+44 (0) 20 7831 3113
About PuriCore
PuriCore plc (LSE: PURI) is a water-based clean technology
company focused on developing and commercialising proprietary
solutions that protect people from the spread of infectious
pathogens without causing harm to human health or the environment.
The Company's products are used in a broad range of markets that
depend upon effective pathogen control including MRSA, e.Coli, and
C. difficile. PuriCore is a leading full provider of all products
and services required for a safe, efficient, and compliant
endoscope decontamination to protect patients in UK hospitals. The
Company's products are the de facto standard for food safety in
leading US supermarket chains. PuriCore also offers a breakthrough
wound therapy solution to treat chronic and acute wounds including
diabetic ulcers and burns. PuriCore has operations in Malvern,
Pennsylvania, US, and in Stafford and Clevedon, UK. To receive
additional information on PuriCore, visit www.puricore.com, which
does not form part of this announcement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAQBLFFXFFEBBL
Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024